This post was originally published on this site OTL38, a tumor-specific fluorescent compound that “lights up” ovarian tumor tissue during surgery, helped doctors to detect and remove cancer cells that would otherwise be missed, final results of a Phase 2 study show. The study, “A phase II, multicenter, open-label trial of OTL38 injection for the…
This post was originally published on this site Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. Under priority review, the approval was based on data from the Phase 3 MAIA trial (NCT02252172), in which…
This post was originally published on this site This week, I want to dive into a topic that’s not always at the top of the list during one’s oncology appointments. Yet it’s something that most of us do regularly (or at least we’d like to be) and it’s something that — surprise, surprise — cancer…
This post was originally published on this site A combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) extends overall survival and the time lived without disease progression in people with newly-diagnosed, inoperable hepatocellular carcinoma (HCC), the most common type of liver cancer, compared to standard-of-care treatment with Nexavar (sorafenib), results from the IMbrave150 Phase 3 trial…
This post was originally published on this site Challenging conventional wisdom, new findings suggest that hormone therapy may have a greater impact than chemotherapy on long-term quality of life in women with breast cancer, particularly those who have gone through menopause. The study, “Differential impact of endocrine therapy and chemotherapy on quality of life of…
This post was originally published on this site Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian cancer, a new study found. These results suggest that Zejula could increase quality of life in addition to slowing cancer growth. The study, “Niraparib Maintenance Treatment…
This post was originally published on this site With the goal of encouraging the multiple myeloma community while raising money to advance treatments, Moving Mountains for Multiple Myeloma (MM4MM) is gearing up for its next expedition — Patagonia. The Nov. 9–19 excursion will take participants across the picturesque, but often-rugged, terrain of the region at the southern end of…
This post was originally published on this site Copiktra (duvelisib), developed by Verastem Oncology, may be an effective and reasonably safe treatment option for people with marginal zone lymphoma who failed to respond to prior therapies including rituximab, Phase 2 data show. The findings were presented at the Lymphoma & Myeloma 2019 International Congress, held Oct. 23-26 in New…
This post was originally published on this site Massachusetts pathologist Lija Joseph, MD, has created an innovative program that allows patients, including those with breast cancer, to actually see the cells that make up their malignancies. In doing so, the hope is that patients will gain the understanding, strength, and knowledge that will help them…
This post was originally published on this site Implementation of routine tumor genetic testing may help identify the approximately 30% of men with metastatic castration-resistant prostate cancer (mCRPC) who may significantly benefit from targeted treatment, namely PARP inhibitors, an international study suggests. The results were presented in a poster, titled “Central, prospective detection of homologous…
